You-Wen He

Dr. You-Wen He

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Trends in Immunology
Verified
Journal Article
Closed access
LLLigong Lu
Ligong Lu
HZHui Zhang
Hui Zhang
DDDanielle J. Dauphars
Danielle J. Dauphars
YHYou-Wen He
You-Wen He

1 January 2012 in Protein & Cell
Verified
Journal Article
Open access
PDF file
CGClaire Gordy
Claire Gordy
YHYou-Wen He
You-Wen He
Recent advances in the understanding of the molecular processes contributing to autophagy have provided insight into the relationship between autophagy and apoptosis. In contrast to the concept of “autophagic cell death,” accumulating evidence suggests that autophagy serves a largely cytoprotective role in physiologically relevant conditions. The cytoprotective function of autophagy is mediated in many circumstances by negative modulation of apoptosis. Apoptotic signaling, in turn, serves to inhibit autophagy. While the mechanisms mediating the complex counter-regulation of apoptosis and autophagy are not yet fully understood, important points of crosstalk include the interactions between Beclin-1 and Bcl-2/Bcl-xL and between FADD and Atg5, caspase- and calpain-mediated cleavage of autophagy-related proteins, and autophagic degradation of caspases. Continued investigation of these and other means of crosstalk between apoptosis and autophagy is necessary to elucidate the mechanisms controlling the balance between survival and death both under normal conditions and in diseases including cancer.

31 August 2016 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YWYu Wang
Yu Wang
SSSheng-Nan Sun
Sheng-Nan Sun
QLQing Liu
Qing Liu
YYYang-Yang Yu
Yang-Yang Yu
JGJian Guo
Jian Guo
YHYou-Wen He
You-Wen He
In contrast to its inhibitory effects on many cells, IL10 activates CD8+ tumor-infiltrating lymphocytes (TIL) and enhances their antitumor activity. However, CD8+ TILs do not routinely express IL10, as autocrine complement C3 inhibits IL10 production through complement receptors C3aR and C5aR. CD8+ TILs from C3-deficient mice, however, express IL10 and exhibit enhanced effector function. C3-deficient mice are resistant to tumor development in a T-cell– and IL10-dependent manner; human TILs expanded with IL2 plus IL10 increase the killing of primary tumors in vitro compared with IL2-treated TILs. Complement-mediated inhibition of antitumor immunity is independent of the programmed death 1/programmed death ligand 1 (PD-1/PD-L1) immune checkpoint pathway. Our findings suggest that complement receptors C3aR and C5aR expressed on CD8+ TILs represent a novel class of immune checkpoints that could be targeted for tumor immunotherapy. Moreover, incorporation of IL10 in the expansion of TILs and in gene-engineered T cells for adoptive cell therapy enhances their antitumor efficacy.Significance: Our data suggest novel strategies to enhance immunotherapies: a combined blockade of complement signaling by antagonists to C3aR, C5aR, and anti–PD-1 to enhance anti–PD-1 efficacy; a targeted IL10 delivery to CD8+ TILs using anti–PD-1–IL10 or anti-CTLA4–IL10 fusion proteins; and the addition of IL10 in TIL expansion for adoptive cellular therapy. Cancer Discov; 6(9); 1022–35. ©2016 AACR.See related commentary by Peng et al., p. 953.This article is highlighted in the In This Issue feature, p. 932

20 February 2020 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
QWQian-Ting Wang
Qian-Ting Wang
YNYing Nie
Ying Nie
SSSheng-Nan Sun
Sheng-Nan Sun
TLTao Lin
Tao Lin
RHRu-Jin Han
Ru-Jin Han
YHYou-Wen He
You-Wen He

7 November 2013 in Blood
Verified
Journal Article
Open access
PDF file
BXBin Xiao
Bin Xiao
YWYu Wang
Yu Wang
WLWei Li
Wei Li
MBMegan Baker
Megan Baker
JGJian Guo
Jian Guo
YHYou-Wen He
You-Wen He
Key Points: Identification of a miRNA panel as a biomarker for the diagnosis, prognosis, and prediction of acute graft-versus-host disease.

16 November 2015 in Autophagy
Verified
Journal Article
Open access
WJWei Jia
Wei Jia
MHMing-Xiao He
Ming-Xiao He
IMIan X McLeod
Ian X McLeod
JGJian Guo
Jian Guo
DJDong Ji
Dong Ji
YHYou-Wen He
You-Wen He
The highly conserved cellular degradation pathway, macroautophagy, regulates the homeostasis of organelles and promotes the survival of T lymphocytes. Previous results indicate that Atg3-, Atg5-, or Pik3c3/Vps34-deficient T cells cannot proliferate efficiently. Here we demonstrate that the proliferation of Atg7-deficient T cells is defective. By using an adoptive transfer and Listeria monocytogenes (LM) mouse infection model, we found that the primary immune response against LM is intrinsically impaired in autophagy-deficient CD8+ T cells because the cell population cannot expand after infection. Autophagy-deficient T cells fail to enter into S-phase after TCR stimulation. The major negative regulator of the cell cycle in T lymphocytes, CDKN1B, is accumulated in autophagy-deficient naïve T cells and CDKN1B cannot be degraded after TCR stimulation. Furthermore, our results indicate that genetic deletion of one allele of CDKN1B in autophagy-deficient T cells restores proliferative capability and the cells can enter into S-phase after TCR stimulation. Finally, we found that natural CDKN1B forms polymers and is physiologically associated with the autophagy receptor protein SQSTM1/p62 (sequestosome 1). Collectively, autophagy is required for maintaining the expression level of CDKN1B in naïve T cells and selectively degrades CDKN1B after TCR stimulation.